Citron DM, Goldstein EJ, Merriam CV, et al: Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 45: 2819, 2007.
Lipsky BA, Tabak YP, Johannes RS, et al: Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia 53: 914, 2010.
Martinez-Gomez Dde A, Ramirez-Almagro C, Campillo-Soto A, et al: Diabetic foot infections: prevalence and antibiotic sensitivity of the causative microorganisms [in Spanish]. Enferm Infecc Microbiol Clin 27: 317, 2009.
Sharma VK, Khadka PB, Joshi A, et al: Common pathogens isolated in diabetic foot infection in Bir Hospital. Kathmandu Univ Med J (KUMJ) 4: 295, 2006.
Abdulrazak A, Bitar ZI, Al-Shamali AA, et al: Bacteriological study of diabetic foot infections. J Diabetes Complications 19: 138, 2005.
Ertugrul BM, Oncul O, Tulek N, et al: A prospective, multi-center study: factors related to the management of diabetic foot infections. Eur J Clin Microbiol Infect Dis 31: 2345, 2012.
Kandemir O, Akbay E, Sahin E, et al: Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. J Infect 54: 439, 2007.
Bansal E, Garg A, Bhatia S, et al: Spectrum of microbial flora in diabetic foot ulcers. Indian J Pathol Microbiol 51: 204, 2008.
El-Tahawy AT: Bacteriology of diabetic foot. Saudi Med J 21: 344, 2000.
Raja NS: Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases. J Microbiol Immunol Infect 40: 39, 2007.
Shankar EM, Mohan V, Premalatha G, et al: Bacterial etiology of diabetic foot infections in South India. Eur J Int Med 16: 567, 2005.
Al Benwan K, Al Mulla A, Rotimi VO: A study of the microbiology of diabetic foot infections in a teaching hospital in Kuwait. J Infect Public Health 5: 1, 2012.
Lipsky BA, Berendt AR, Cornia PB, et al: 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 54: e132, 2012.
Lipsky BA, Itani K, Norden C, et al: Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 38: 17, 2004.
Graham DR, Lucasti C, Malafaia O, et al: Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 34: 1460, 2002.
Noel GJ, Bush K, Bagchi P, et al: A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 46: 647, 2008.
Lipsky BA, Armstrong DG, Citron DM, et al: Ertapanem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 366: 1695, 2005.
CDC/NHSN surveillance definitions for specific types of infections. Available at: http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf. Accessed October 10, 2013.
Harris PA, Taylor R, Thielke R, et al: Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Informatics 42: 377, 2009.
Jenkins TC, Irwin A, Coombs L, et al: Effects of clinical pathways for common outpatient infections on antibiotic prescribing. Am J Med 126: 327, 2013.
Gottesman BS, Carmeli Y, Shitrit P, et al: Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 49: 869, 2009.
Batard E, Ollivier F, Boutoille D, et al: Relationship between hospital antibiotic use and quinolone resistance in Escherichia coli. Int J Infect Dis 17: e254, 2013.
Pseudomonas aeruginosa has traditionally been considered a common pathogen in diabetic foot infection (DFI), yet the 2012 Infectious Diseases Society of America guideline for DFI states that “empiric therapy directed at P aeruginosa is usually unnecessary.” The objective of this study was to evaluate the frequency of P aeruginosa isolated from bone or tissue cultures from patients with DFI.
This study is a cross-sectional survey of diabetic patients presenting with a foot infection to an urban county hospital between July 1, 2012, and December 31, 2013. All of the patients had at least one debridement procedure during which tissue or bone cultures from operative or bedside debridements were obtained. The χ2 test and the t test of means were used to determine relationships between variables and the frequency of P aeruginosa in culture.
The median number of bacteria isolated from DFI was two. Streptococcus spp and Staphylococcus aureus were the most commonly isolated organisms; P aeruginosa was isolated in only five of 112 patients (4.5%). The presence of P aeruginosa was not associated with the patient's age, glycosylated hemoglobin level, tobacco abuse, the presence of osteomyelitis, a prescription for antibiotic drugs in the preceding 3 months, or the type of operative procedure.
Pseudomonas aeruginosa was an infrequent isolate from DFI in this urban, underserved diabetic population. The presence of P aeruginosa was not associated with any measured risk factors. By introducing a clinical practice guideline, we hope to discourage frontline providers from using routine antipseudomonal antibiotic drugs for DFI.
Division of Infectious Diseases, Denver Health Medical Center, Denver, CO.